Ulla Feldt-Rasmussen
Clinical Professor
Department of Clinical Medicine
Blegdamsvej 9, 2100 København Ø
341 - 344 out of 344Page size: 10
- Published
The influence of alpha 1-acid glycoprotein (orosomucoid) and its glycoforms on the function of human thyrocytes and CHO cells transfected with the human TSH receptor
Zimmermann-Belsing, T., Rasmussen, Å. K., Feldt-Rasmussen, Ulla & Bøg-Hansen, T. C., 2002, In: Mol Cell Endocrin. 188, p. 241-251Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Circulating leptin and thyroid dysfunction.
Zimmermann-Belsing, T., Brabant, G., Holst, Jens Juul & Feldt-Rasmussen, Ulla, 2003, In: European Journal of Endocrinology. 149, 4, p. 257-71 14 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Thyrotropin-releasing hormone stimulation test in patients with pituitary pathology.
pxw866, P., Hartoft-Nielsen, M., Rasmussen, Å. K., Zimmermann-Belsing, T. & Feldt-Rasmussen, Ulla, 2004, In: Hormone Research. 61(2):53-7Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Current clinical practice for thromboprophylaxis management in patients with Cushing’s syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN)
Endo-ERN Cushing and Thrombosis study group, E. C. A. T. S. G., 2022, In: Orphanet Journal of Rare Diseases. 17, 178.Research output: Contribution to journal › Journal article › Research › peer-review
ID: 916030
Most downloads
-
11641
downloads
Recent advances in understanding autoimmune thyroid disease: the tallest tree in the forest of polyautoimmunity
Research output: Contribution to journal › Review › Research › peer-review
Published -
2166
downloads
The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
280
downloads
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
Research output: Contribution to journal › Journal article › Research › peer-review
Published